Washington, D.C.-There’s a lot of talk in Washington about the importance of enacting legislation to establish a pathway for FDA to approve “similar” or “follow-on” versions of biotech drugs. Biopharmaceutical companies have been pushing for compromise legislation this year, that is aligned with health insurers, pharmacy benefit managers, and public and private payers, who envision big savings.
Washington, D.C.-There’s a lot of talk in Washington about the importance of enacting legislation to establish a pathway for FDA to approve “similar” or “follow-on” versions of biotech drugs. Biopharmaceutical companies have been pushing for compromise legislation this year, that is aligned with health insurers, pharmacy benefit managers, and public and private payers, who envision big savings.
Stakeholders see savings from access to generic versions of insulin, human growth hormone and erythropoietin, just to start.
Last year, leading senators developed a compromise follow-on biologics bill (S. 1695), but got stuck over language defining an exclusivity period for innovator therapies. Several biosimilar bills have been introduced in the House, but committee leaders have not taken any action on the issue.
Some agreement is emerging on key issues. Innovators and generics makers acknowledge that most biosimilars would warrant some clinical testing to assess immunogenicity and that the Food and Drug Administration should have flexibility to determine the viability of a proposed follow-on product. The main sticking point is over how long a data exclusivity period is needed to maintain incentives for innovation, as well as opportunities to develop follow-on products. If there’s a deal on these issues, the legislators could put together a compromise bill quickly and push it through with late-session must-pass budget legislation. But the details are complicated, and the betting is against any last-minute action this year.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
With PrEP Effort Lagging, Positive Results for Twice-Yearly Lenacapavir May Give a Lift | AIDS 2024
July 25th 2024Phase 3 trials reported at the International AIDS Society meeting this week show no infections among those randomly assigned to twice-year injections of lenacapavir and no reason to be worried about safety,.
Read More
A Renewed Commitment to HIV Vaccine Development Despite Advancements in Antiretrovirals | AIDS 2024
July 25th 2024The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.
Read More